Insider trading

Period: 120 months Stock: PRLD + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

65 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

65 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

65 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

65 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
65 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
65 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

65 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
21 Apr 2026
ORBIMED ADVISORS LLC Director · indirect
Bought 2×
$12.50M 2,815,315 at 4.44
31.3%
Largest buy in 3 yrs
21 Apr 2026
Bonita David P Director · indirect
Bought 2×
$12.50M 2,815,315 at 4.44
31.3%
Largest buy in 3 yrs
25 Mar 2025
Bought
$467.44K 675,000 at 0.69
51.0%
Largest buy in 3 yrs
25 Mar 2025
Combs Andrew Chief Chemistry Officer
Bought
$69.25K 100,000 at 0.69
26.3%
+26% of stake
21 Mar 2025
Bought
$10.96K 15,000 at 0.73
1.1%
20 Mar 2025
Bought
$3.95K 5,416 at 0.73
0.4%
17 Mar 2025
Bought
$6.83K 9,106 at 0.75
0.7%
14 Mar 2025
Bought
$22.63K 29,999 at 0.75
2.4%
13 Mar 2025
Bought
$35.82K 50,000 at 0.72
4.1%
12 Mar 2025
Bought
$33.74K 47,500 at 0.71
4.1%
31 Dec 2024
Vaddi Krishna CEO · indirect
Bought
$6.04K 5,000 at 1.21
3.6%
30 Dec 2024
Vaddi Krishna CEO · indirect
Bought
$12.00K 10,000 at 1.20
7.8%
23 Dec 2024
Combs Andrew Chief Chemistry Officer
Bought
$82.00K 60,000 at 1.37
18.9%
Largest buy in 3 yrs
20 Dec 2024
Combs Andrew Chief Chemistry Officer
Bought
$3.54K 3,075 at 1.15
1.0%
First buy in 3+ yrs
19 Dec 2024
Lim Bryant David CLO, Interim CFO, Corp Sec.
Bought
$22.64K 25,000 at 0.91
×10
Largest buy in 3 yrs
19 Dec 2024
Vaddi Krishna CEO · indirect
Bought
$6.12K 6,888 at 0.89
5.7%
18 Dec 2024
Bought
$93.21K 100,000 at 0.93
9.4%
25 May 2023
Bought
$4.78K 900 at 5.31
0.1%
24 May 2023
Lim Bryant David Chief Legal Officer, Corp Sec.
Bought
$12.94K 2,400 at 5.39
opened
First buy on file
24 May 2023
Bought
$5.01K 1,000 at 5.01
0.1%
23 May 2023
Bought
$66.75K 11,856 at 5.63
1.1%
23 May 2023
Chardonnet Laurent Chief Financial Officer
Bought
$27.50K 5,000 at 5.50
13.5%
22 May 2023
Bonita David P Director · indirect
Bought
$5.00M 869,565 at 5.75
9.4%
First buy on file
22 May 2023
ORBIMED ADVISORS LLC Director · indirect
Bought
$5.00M 869,565 at 5.75
9.4%
First buy on file
6 Apr 2023
Huang Jane President, CMO
Sold at will
$81.27K 13,280 at 6.12
35.4%
Not planned
20 Dec 2022
Vaddi Krishna CEO · indirect
Bought
$98.45K 19,188 at 5.13
18.9%
First buy on file
8 Dec 2022
Chardonnet Laurent Chief Financial Officer
Bought
$47.60K 10,000 at 4.76
38.7%
Largest buy in 3 yrs
1 Jun 2022
Chardonnet Laurent Chief Financial Officer
Bought
$42.30K 10,000 at 4.23
69.0%
First buy on file
15 Dec 2021
Morosini Deborah EVP, Chief of Clinical Affairs
Sold, plan not stated
$373.76K 28,751 at 13.00
98.5%
Sold half or more
14 Dec 2021
Combs Andrew EVP, Head of Chemistry
Bought
$46.40K 4,000 at 11.60
1.5%
13 Dec 2021
Combs Andrew EVP, Head of Chemistry
Bought
$48.48K 4,000 at 12.12
1.5%
First buy on file
16 Nov 2021
Morosini Deborah EVP, Chief of Clinical Affairs
Sold, plan not stated 2×
$456.53K 28,751 at 15.88
98.5%
Sold half or more
5 Oct 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$464.35K 15,000 at 30.96
100%
Sold half or more
7 Sep 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$550.28K 15,000 at 36.69
100%
Sold half or more
2 Sep 2021
Pierce Christopher EVP and Chief of Business Oper
Sold, plan not stated 3×
$708.49K 17,000 at 41.68
81.9%
Sold half or more
27 Aug 2021
Scherle Peggy Chief Scientific Officer
Sold, plan not stated 3×
$215.97K 6,014 at 35.91
3.4%
26 Aug 2021
Scherle Peggy Chief Scientific Officer
Sold, plan not stated
$59.82K 1,700 at 35.19
1.0%
25 Aug 2021
Piper Brian Chief Financial Officer
Sold, plan not stated 3×
$277.83K 8,333 at 33.34
100%
Sold half or more
13 Aug 2021
Scherle Peggy Chief Scientific Officer
Sold, plan not stated
$80.16K 2,286 at 35.07
1.3%
5 Aug 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 4×
$466.39K 15,000 at 31.09
100%
Sold half or more
27 Jul 2021
Scherle Peggy Chief Scientific Officer
Sold, plan not stated 2×
$709.38K 20,000 at 35.47
10.4%
6 Jul 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$412.11K 15,000 at 27.47
100%
Sold half or more
7 Jun 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$486.62K 15,000 at 32.44
100%
Sold half or more
25 May 2021
Piper Brian Chief Financial Officer
Sold, plan not stated 4×
$285.54K 8,333 at 34.27
100%
Sold half or more
7 May 2021
Scherle Peggy Chief Scientific Officer
Sold, plan not stated 3×
$408.19K 10,000 at 40.82
5.5%
5 May 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$602.09K 15,000 at 40.14
100%
Sold half or more
29 Apr 2021
Pierce Christopher EVP and Chief of Business Oper
Sold, plan not stated
$132.76K 3,295 at 40.29
46.8%
29 Apr 2021
Morosini Deborah EVP, Chief of Clinical Affairs
Sold, plan not stated
$129.85K 3,223 at 40.29
87.9%
Sold half or more
27 Apr 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 3×
$884.85K 25,000 at 35.39
100%
Sold half or more
19 Apr 2021
Mauro David J Chief Medical Officer
Sold, plan not stated 2×
$772.35K 25,000 at 30.89
100%
Sold half or more
Showing 1–50 of 65. Page 1 of 2 Older →